Convened under the auspicious of esteemed endorsers - ISTA

We present the results of a consecutive series of 500 total hip replacements using C-stemfemoral components, performed between March 2000 and December 2005 at a singleinstitution. Data was collected prospectively and all patients remain under annual follow-up bya Specialist Arthroplasty Practitioner. The operations were performed using a standard surgicaltechnique with third generation cementing using Palacos-R antibiotic loaded cement.500 arthroplasties were performed on 455 patients with an average age at the time of surgery of68.3 years (23-92). There were 282 (62%) female and 173 (38%) male patients withosteoarthritis being the predominant diagnosis. 77 patients have died (73 hips) and the averageduration of follow-up for the entire series is 81 months (52-124).Only 2 femoral implants have been revised - one for deep sepsis and the other as part of arevision procedure for a loose acetabulum, although the femoral component itself was not loose.One implant is currently loose following a periprosthetic fracture treated by internal fixation, butnone of the remaining implants demonstrates any progressive radiolucencies in any Gruenzones or any features suggestive of current or future loosening. Calcar rounding has beenobserved, but there have been no cases with obvious loss of calcar height and no cases of distalfemoral cortical hypertrophy.The C-stem femoral component has therefore performed well in clinical practice and theobjective of eradicating negative bone remodelling has been achieved. The study is ongoing.Thursday, October 7, 2010, 16:50-17:40Session B8: Management of Complications in TKARivaroxaban Versus Enoxaparin in the Setting of Elective Hip and KneeArthroplasty and Their Effects on Bleeding, Thromboembolism andDelayed Wound HealingIntroduction*Barry Rose - East Ken Hospitals NHS Foundation Trust - Margate, UKKatia Sindali - East Kent Hospitals NHS Foundation Trust - Margate, UKHassan Soueid - East Kent Hospitals NHS Foundation Trust - Margate, UKChan Jeer - East Kent Hospitals NHS Foundation Trust - Margate, UKDeepak Saran - East Kent Hospitals NHS Foundation Trust - Margate, UK*Email: barryrose@doctors.org.ukRivaroxaban is the first licensed oral direct inhibitor of factor Xa. Recent studies from theRECORD trials suggest rivaroxaban has superior efficacy compared to enoxaparin in preventingvenous thromboembolism (VTE) with no significant increase in the major bleeding risk.file:///E|/ISTA2010-Abstracts.htm[12/7/2011 3:15:47 PM]